Harvard Bioscience Inc.

Harvard Bioscience initially fell out of Nasdaq compliance in April.

Jim Green will retire from his roles as chairman, president, and CEO of Harvard Bioscience on July 28.

Harvard Bioscience, a Holliston-based biotech firm, has fallen out of compliance with Nasdaq stock exchange requirements following the resignation of a board of directors member.

The CFO of Harvard Bioscience in Holliston is set to step down from her role after a three-year stint with the company. 

Ernie Herrman, president and CEO of The TJX Cos. in Framingham, was the highest-paid CEO among Central Massachusetts public companies for fiscal 2023.

The amount of employees that will be impacted by the cuts was not disclosed.

Holliston biotech firm Biostage has rebranded back to its former name, Harvard Apparatus Regenerative Technology.

Jennifer Cote has served as interim CFO at Holliston-based Harvard Bioscience since January. The life science equipment manufacturer has now moved to make that role permanent, effective immediately, according to a Tuesday press release from the life science developer.

Harvard Bioscience, Inc. named Jennifer Cote as the company’s chief financial officer and treasurer following the resignation of Michael Rossi, according to a Monday press release from the company.

Harvard Bioscience, a life science equipment manufacturer based in Holliston, reported a net loss of $410,000 for the company’s second quarter financials in an earnings report released on Thursday.